Parma, 22 September 2026 – Maria Paola Chiesi, Chair of the Board of Chiesi Group, has joined the Chairs of several leading healthcare companies in signing an open letter urging policymakers to consider investment in health and innovation as a strategic priority for Europe's future competitiveness,…
Chiesi Farmaceutici has announced a strategic partnership with Abdi İbrahim to implement a new operating model for Chiesi’s business in Türkiye. Effective 1 October 2026, the partnership will combine Chiesi's global scientific expertise, innovative portfolio and high-quality standards with Abdi…
Following Chiesi's evaluation of the seralutinib development program and the PROSERA Phase 3 study results, Chiesi and Gossamer Bio have agreed to terminate their Collaboration and License Agreement related to the development and commercialization of seralutinib for the treatment of patients with…
Gossamer Bio released today the topline results from the Phase 3 PROSERA clinical study evaluating seralutinib, an investigational inhaled therapy, in people living with pulmonary arterial hypertension (PAH). Gossamer Bio and Chiesi are jointly developing seralutinib under a global collaboration…
Today marks the one-year anniversary of the passing of Dr. Paolo Chiesi, former Honorary President of Chiesi Group. Dr. Paolo Chiesi was a visionary leader and a cornerstone of Chiesi Group for almost sixty years. His contributions to scientific progress and innovation have left a lasting impact on…
Collaboration, co-creation and the exchange of ideas were at the heart of the Code of Interdependence workshop. The event was an opportunity to strengthen the Chiesi Group's strategic collaboration and to promote innovative solutions from the perspective of Chiesi's partners. The Code of…
Eight abstracts from Chiesi’s global respiratory research portfolio will be presented at the American Thoracic Society (ATS) 2024 International Conference in San Diego starting from May 17, 2024. Presentations include preclinical and clinical stage global studies in asthma, Chronic Obstructive…
In 1936, Neive Terzi became the first female researcher hired at Chiesi, a year after the company was founded as a pioneer in the healthcare field. Not only was she the first employee with a degree at the time, but she laid the foundation of a journey of women empowerment that has become deeply…
Trust, Future, Sinergy, Resilience. They are just few of the key words around which the definition of partnership was built during the fourth Chiesi Partnership Day. An event dedicated to the celebration and awarding of Chiesi Group’s strategic partners that have distinguished themselves in terms of…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
